During the COVID-19 pandemic, the development of prophylactic vaccines, including those based on new platforms, became highly relevant. One such platform is the creation of vaccines combining DNA and protein components in one construct. For the creation of DNA vaccine, we chose the full-length spike protein (S) of the SARS-CoV-2 virus and used the recombinant receptor-binding domain (RBD) of the S protein produced in CHO-K1 cells as a protein component. The immunogenicity of the developed combined vaccine and its individual components was compared and the contribution of each component to the induction of the immune response was analyzed. The combined DNA/protein vaccine possesses the advantages of both underlying approaches and is capable of inducing both humoral (similar to subunit vaccines) and cellular (similar to DNA vaccines) immunity.
展开▼
机译：在 COVID-19 大流行期间，预防性疫苗的开发（包括基于新平台的疫苗）的开发变得非常重要。其中一个平台是将DNA和蛋白质成分结合在一个结构中的疫苗。为了制造 DNA 疫苗，我们选择了 SARS-CoV-2 病毒的全长刺突蛋白 （S），并使用 CHO-K1 细胞中产生的 S 蛋白的重组受体结合域 （RBD） 作为蛋白质成分。比较了开发的联合疫苗及其各个成分的免疫原性，并分析了每种成分对免疫反应诱导的贡献。DNA/蛋白质联合疫苗具有两种基本方法的优点，能够诱导体液免疫（类似于亚单位疫苗）和细胞免疫（类似于 DNA 疫苗）。
展开▼
